Financial Performance - Total revenue for the six months ended June 30, 2024, was RMB 187,326,000, an increase of 6.8% compared to RMB 175,623,000 for the same period in 2023[3] - Revenue from medical devices and consumables trading was RMB 160,410,000, up 9% from RMB 147,171,000 year-on-year[3] - The company reported a net profit of RMB 6,183,000 for the period, compared to RMB 5,764,000 in the previous year, reflecting a growth of 7.3%[3] - Basic and diluted earnings per share for the period were RMB 1.41, a decrease from RMB 1.53 in the prior period[3] - Total revenue from customer contracts reached RMB 180,343 thousand in the first half of 2024, compared to RMB 162,742 thousand in 2023, marking an increase of 10.8%[9] - The net profit for the first half of 2024 was RMB 6,042 thousand, slightly down from RMB 6,115 thousand in 2023, a decrease of 1.2%[17] - The company reported RMB 5,681 thousand in guarantees as of June 30, 2024, slightly down from RMB 6,934 thousand as of December 31, 2023[21] - The company recorded revenue of approximately RMB 187.3 million, an increase of about RMB 11.7 million or 6.7% from the previous period's RMB 175.6 million[37] Asset and Liability Management - Non-current assets increased to RMB 181,582,000 as of June 30, 2024, compared to RMB 155,592,000 as of December 31, 2023, representing a growth of 16.7%[4] - The company’s cash and cash equivalents stood at RMB 474,335,000, up from RMB 459,571,000 at the end of 2023, indicating a slight increase of 3.3%[4] - Total liabilities decreased to RMB 104,826,000 from RMB 259,931,000, showing a significant reduction of 59.7%[5] - Trade receivables stood at RMB 186,789 thousand as of June 30, 2024, down from RMB 206,411 thousand in December 2023, a decrease of 9.5%[19] - The expected credit loss provision for financing lease receivables increased to RMB 27,330 thousand in June 2024, up from RMB 24,470 thousand in December 2023, an increase of 11.5%[18] - The company's trade payables decreased to RMB 25,937 thousand as of June 30, 2024, from RMB 59,611 thousand as of December 31, 2023, reflecting a decrease of approximately 56.5%[27] - The company's bank borrowings due within one year increased to RMB 82,100 thousand as of June 30, 2024, from RMB 53,789 thousand as of December 31, 2023, representing an increase of approximately 52.5%[26] Operational Highlights - The company plans to expand its product offerings in the medical device sector and enhance its technology services[3] - The company is exploring potential mergers and acquisitions to strengthen its market position and drive future growth[3] - Monthly service revenue decreased to RMB 11,924 thousand in the first half of 2024, down from RMB 15,571 thousand in 2023, a decline of 23.4%[9] - Financing lease income decreased to RMB 6,983 thousand in the first half of 2024, down from RMB 12,875 thousand in 2023, a decline of 45.8%[9] - Revenue from the financing leasing services decreased to RMB 7.0 million during the period, attributed to a decline in business volume and funding needs from potential clients[33] - Revenue from the maternal and infant service industry recorded RMB 11.9 million, impacted by a weak market atmosphere and declining birth rates in China[34] Employee and Cost Management - The total employee costs amounted to RMB 15,014 thousand in the first half of 2024, down from RMB 21,981 thousand in 2023, a reduction of 31.2%[14] - Employee costs decreased from approximately RMB 20.7 million to about RMB 13.7 million[39] - The total employee cost for the period was approximately RMB 13.7 million, down from RMB 20.7 million in the previous period, with a reduction in the number of employees from 258 to 161[54] Corporate Governance and Compliance - The group has maintained its accounting policies consistent with those used in the previous financial year, ensuring stability in financial reporting[7] - The audit committee reviewed the unaudited consolidated financial statements for the six months ended June 30, 2024, confirming compliance with applicable accounting standards and regulations[62] - The group has maintained compliance with the corporate governance code, with no significant deviations reported[58] - There are no major events affecting the group that occurred after June 30, 2024, up to the date of this announcement[60] Capital and Investment Activities - The company plans to issue up to 86,000,000 shares at a subscription price of HKD 1.00 per share, pending the fulfillment of conditions in the underwriting agreement[31] - The company issued 30 million subscription shares at HKD 1.47 per share, raising approximately HKD 43.5 million for working capital to develop its medical device and consumable trading business[47] - The group's capital commitments for the acquisition of subsidiaries and procurement of computer software amounted to RMB 5.3 million, a decrease from RMB 18.8 million as of December 31, 2023[49] - The group completed the acquisition of Wuhan Meikangmao Health Management Co., Ltd. for RMB 40.0 million on April 2024, which provides maternity services in China[51] - The group did not engage in any significant investments, acquisitions, or disposals of subsidiaries during the period, aside from the aforementioned acquisition[51] Other Financial Metrics - The company recorded a fair value gain of RMB 3 thousand on financial assets measured at fair value through profit or loss in the first half of 2024, compared to RMB 4 thousand in 2023[10] - Impairment losses recognized during the period amounted to approximately RMB 1.9 million, compared to RMB 1.7 million in the previous period[40] - Other operating expenses decreased from approximately RMB 21.0 million to about RMB 17.8 million, primarily due to reduced sales and marketing expenses[41] - Financing costs decreased from approximately RMB 7.6 million to about RMB 5.2 million, mainly due to lower interest from bank and other borrowings[42] - As of June 30, 2024, the company's cash and bank balances were approximately RMB 24.1 million, down from RMB 108.3 million as of December 31, 2023[45] - The debt-to-equity ratio increased to approximately 33.2% from 29.6% due to increased bank borrowings for business expansion[45] - The group has not conducted any buybacks, sales, or redemptions of its listed securities during the period[57] - There were no significant contingent liabilities reported as of June 30, 2024[53]

Financing and Investment - The Group's financing leasing services have expanded nationwide, focusing on optimizing industrial structure and resource integration to achieve economic and social benefits[44]. - The Group anticipates that the post-pandemic health industry will become a significant growth point, with plans to focus on medical equipment leasing and trading, diversifying revenue streams[44]. - The Group has adjusted internal return rates to improve asset quality and minimize risks due to increased overdue rates among clients caused by the pandemic[44]. - By 2027, the scale of equipment investment in various industries in China is expected to increase by more than 25% compared to 2023, as outlined in the "Action Plan for Promoting Large-Scale Equipment Renewal and Consumer Goods Replacement" issued by the State Council of China[57]. - The Group's net amount of receivables arising from finance leasing services as of December 31, 2023, was RMB 131,469,000, a decrease from RMB 201,169,000 as of December 31, 2022[68]. - The Group's secured and guaranteed receivables accounted for 99.5% of the total receivables in finance leasing services as of December 31, 2023[68]. - The Group recorded a revenue of RMB 25.1 million from finance leasing services, serving approximately 4,800 SMEs across 30 provinces in China as of December 31, 2023[87][88]. - The Group's finance leasing services include direct finance leasing and sale-leaseback options, enhancing operational expertise in the medical equipment industry[87][88]. - The Group's finance lease receivables and loan receivables were approximately RMB 72.1 million as of December 31, 2023, down from RMB 143.5 million in 2022[145]. Risk Management - The Group's commitment to risk management is central to its strategy in response to the pandemic's effects on client performance[44]. - The Group has developed a risk management system tailored to its business operations, focusing on comprehensive due diligence and multi-level approval processes to mitigate various risks[63]. - The Group's risk management committee evaluates finance leasing transactions through a detailed assessment process, ensuring that customer entry criteria are met before approval[65]. - The Group's management assessed expected credit losses based on trade receivables and other financial instruments, reflecting a proactive approach to credit risk management[113]. - Impairment losses under the expected credit loss model were approximately RMB6.0 million this year, down from approximately RMB9.2 million in the previous year[140]. - An additional impairment loss of approximately RMB6.0 million was recognized due to the impact of COVID-19, affecting the customers' past due ratio[111]. Corporate Governance and Board Activities - The Board convened six full Board meetings during the year to review financial and operational performance and approve overall strategies[33]. - The Group's corporate governance practices include well-documented board meeting minutes and resolutions[151]. - The Board held six meetings during the year, with all directors attending[146]. - The Remuneration Committee reviewed the remuneration packages for directors and senior management, considering business performance and market conditions[155]. - The Nomination Committee will continue to monitor diversity aspects in board appointments and recommend actions as necessary[152]. - The Group's commitment to equal opportunities includes a non-discrimination policy based on various factors such as gender and nationality[152]. Financial Performance - The Group's revenue increased by approximately RMB173.4 million or approximately 53.4%, from approximately RMB324.6 million for the year ended 31 December 2022 to approximately RMB498.0 million for the Year[133]. - Revenue from trading of medical equipment and consumables increased from approximately RMB236.5 million for the Prior Year to approximately RMB417.0 million for the Year[133]. - Operating lease income increased from RMB nil for the Prior Year to approximately RMB0.8 million for the Year[133]. - Income from IT services increased from RMB nil for the Prior Year to approximately RMB26.6 million for the Year[133]. - The cost of medical equipment and consumables sold increased from approximately RMB185.6 million for the Prior Year to approximately RMB375.0 million for the Year[134]. - Profit attributable to owners of the Company decreased to approximately RMB14.6 million this year from RMB15.8 million in the previous year[142]. - As of December 31, 2023, bank balances and cash were approximately RMB108.3 million, up from RMB13.7 million in 2022[144]. - The Group's working capital was approximately RMB199.6 million as of December 31, 2023, down from RMB233.7 million in 2022[144]. - The gearing ratio decreased to approximately 29.6% as of December 31, 2023, from 42.4% in 2022[144]. Employee and Social Responsibility - As of December 31, 2023, the Group had 184 employees, a decrease from 281 employees in 2022[200]. - Total staff cost for the year was approximately RMB41.6 million, down from RMB45.8 million in 2022[200]. - Employee retirement benefit expense for the year was approximately RMB4.7 million, compared to RMB6.0 million in 2022[200]. - The Group participates in various employee social security plans administered by local government[200]. - Remuneration policy rewards employees and Directors based on individual performance and Group performance[200]. - Performance bonuses are offered to qualified employees based on individual and Group performance[200]. - The Group did not experience any material labor disputes during the year[200]. Strategic Initiatives and Future Outlook - The Group is focused on enhancing its services in the maternal and child postpartum care industry through digitization and intelligence, aiming to build a comprehensive mother and baby ecosystem[58]. - The Group entered into an investment agreement to acquire a 51% equity interest in Wuhan Desheng Meimei Health Management Co., Ltd. for RMB 3.4 million, expanding its footprint in postpartum care services[70]. - The Group aims to consolidate its services in the maternal and child postpartum care industry, leveraging modern medicine to enhance service quality and customer experience[58]. - New product development initiatives are underway, focusing on enhancing the maternal and child postpartum care business, which is expected to contribute an additional $10 million in revenue[186]. - The company is exploring market expansion opportunities in Southeast Asia, aiming to increase its market share by 10% in the region[186]. - A strategic acquisition is planned to enhance the company's supply chain capabilities, with an estimated investment of $5 million[186]. - The company has set a future outlook with a revenue target of $180 million for the next fiscal year, indicating a growth of 20%[178].

Revenue and Profit - Total revenue for 2023 reached RMB 497,955 thousand, with the trade business contributing RMB 416,998 thousand, accounting for the largest share[8] - The company's net profit attributable to equity holders was RMB 312,447 thousand in 2023, compared to RMB 306,861 thousand in 2022[6] - The company's trade business revenue grew significantly to RMB 416,998 thousand in 2023 from RMB 236,539 thousand in 2022, representing a 76.2% increase[25] - Total revenue increased to RMB 497.955 million in 2023, up from RMB 324.598 million in 2022, driven by growth in medical equipment and consumables trade revenue, which rose to RMB 416.998 million from RMB 236.539 million[82] - Revenue increased by approximately RMB 173.4 million or 53.4%, from RMB 324.6 million in the previous year to RMB 498.0 million in the current year, primarily driven by growth in medical equipment and consumables trade revenue, which rose from RMB 236.5 million to RMB 417.0 million[120] - Medical device and consumables trade business revenue reached RMB 417.0 million for the year[128] - Net profit attributable to the company's owners decreased to RMB 14.563 million in 2023, compared to RMB 15.813 million in 2022[82] - The company's profit attributable to owners for the year was approximately RMB 14.6 million, a decrease from RMB 15.8 million in the previous year[139] Assets and Liabilities - Total assets minus current liabilities increased to RMB 406,509 thousand in 2023 from RMB 355,232 thousand in 2022[3] - The company's total liabilities stood at RMB 299,874 thousand as of December 31, 2023[15] - The company's total assets stood at RMB 615,163 thousand, while total liabilities were RMB 291,460 thousand, reflecting a strong balance sheet position[48][71] - The company's total assets stood at RMB 602.277 million, with cash and bank balances increasing significantly to RMB 108.260 million in 2023 from RMB 13.707 million in 2022[83][94] - The company's total assets across reportable segments amounted to RMB 579.269 million, with the largest segment contributing RMB 349.699 million[124] - Net current assets decreased to RMB 199,640 thousand from RMB 233,689 thousand[188] - Non-current liabilities decreased to RMB 39,943 thousand from RMB 95,692 thousand, with bank and other borrowings dropping to RMB 31,754 thousand from RMB 80,981 thousand[189] - Net asset value increased to RMB 315,289 thousand from RMB 310,817 thousand[189] - Reserves increased to RMB 278,608 thousand from RMB 273,022 thousand[189] - Total equity increased to RMB 315,289 thousand from RMB 310,817 thousand[189] Trade and Receivables - The company's trade receivables aged 1-30 days increased to RMB 162,587 thousand in 2023 from RMB 95,482 thousand in 2022[39] - The company's trade receivables increased from RMB 137,955 thousand in 2022 to RMB 206,411 thousand in 2023, with a corresponding increase in impairment loss provisions from RMB 5,520 thousand to RMB 9,424 thousand[58] - Trade receivables increased to RMB 196.987 million in 2023, up from RMB 132.435 million in 2022, reflecting growth in business activities[83] Maternity Services - The company's maternity services revenue decreased to RMB 28,438 thousand in 2023 from RMB 50,809 thousand in 2022, a 44% decline[25] - Revenue from maternity services decreased to RMB 28.438 million in 2023, down from RMB 50.809 million in 2022, primarily due to pandemic-related restrictions and the closure of 3 maternity centers[82] - The company recorded a segment loss of RMB 5.9 million in the maternity services sector, attributed to operational disruptions and center closures[73] - The company acquired a 51% equity stake in Wuhan Desheng Meimei Health Management Co., Ltd. for RMB 3.4 million, expanding its maternity services portfolio[73] - The maternity services sector is expected to benefit from China's three-child policy, with over 90% of consumers recognizing the professionalism of maternity centers[99] - The company plans to enhance its maternity services through digitalization and intelligent upgrades, aiming to build a comprehensive maternal and infant ecosystem[99] Financing and Leases - The company's bank and other borrowings decreased to RMB 101,047 thousand in 2023 from RMB 147,861 thousand in 2022[17] - The company's financing lease receivables decreased from RMB 201,072 thousand in 2022 to RMB 131,469 thousand in 2023, reflecting a significant reduction in lease obligations[44] - The company provided financing lease services to approximately 4,800 SME clients across 30 provinces, cities, and autonomous regions in China, generating revenue of RMB 25.1 million in 2023[53] - Total bank and other borrowings decreased from RMB 228,842 thousand in 2022 to RMB 132,801 thousand in 2023, indicating a reduction in debt[52] - The company's financing costs for 2023 included RMB 12,447 thousand in bank and other borrowing interest, and RMB 1,400 thousand in lease liability interest[56] - The company's lease liabilities were recorded at RMB 3.453 million[127] - Total financing lease receivables and loan receivables were approximately RMB 72.1 million as of December 31, 2023 (2022: RMB 143.5 million)[131] - Bank and other borrowings due within one year decreased to approximately RMB 101.0 million (2022: RMB 147.9 million), and borrowings due after one year decreased to approximately RMB 31.8 million (2022: RMB 80.9 million)[151] - The asset-liability ratio decreased to approximately 29.6% (2022: 42.4%), mainly due to reduced demand for bank and other borrowings as a result of the decrease in the group's finance lease business[164] Costs and Expenses - The company's R&D costs recognized as expenses were RMB 3,091 thousand in 2023, down from RMB 4,080 thousand in 2022[9] - The company's short-term lease expenses decreased to RMB 1,061 thousand in 2023 from RMB 5,486 thousand in 2022[9] - Sales cost for medical equipment and consumables trade increased from RMB 185.6 million in the previous year to RMB 375.0 million in the current year[109] - The company's employee costs decreased from RMB 42.0 million in the previous year to RMB 38.7 million in the current year[121] - The total employee cost for the year was approximately RMB 41.6 million (2022: RMB 45.8 million), with employee retirement benefit expenses of approximately RMB 4.7 million (2022: RMB 6.0 million)[167] - Other operating expenses decreased from approximately RMB 55.4 million in the previous year to approximately RMB 46.0 million this year, mainly due to reductions in miscellaneous expenses for the maternal and infant business, short-term lease payments, and depreciation of right-of-use assets[149] Investments and Acquisitions - The company acquired a 51% equity stake in Wuhan Desheng Meimei Health Management Co., Ltd. for RMB 3.4 million, expanding its maternity services portfolio[73] - The company entered into a share transfer agreement to acquire Wuhan Meikangmao Health Management Co., Ltd. for RMB 40.0 million, though the transaction has not yet been completed as of December 31, 2023[143] - The group did not engage in any significant acquisitions or disposals of subsidiaries or associates during the year[154] Dividends and Share Capital - The company declared a final dividend of 2.5 HK cents per share for the year, consistent with the previous year's dividend[87] - No final dividend is recommended for the year ended December 31, 2023 (2022: 2.5 HK cents)[173] - The company's issued share capital was HKD 40,000,000 with 400,000,000 ordinary shares issued as of December 31, 2023[141] - The group's capital structure remains unchanged since its listing on the GEM of the Hong Kong Stock Exchange on July 9, 2018, with only ordinary shares in its share capital[165] Impairment and Losses - The company recorded a goodwill impairment loss of RMB 1.2 million due to the underperformance of one of its subsidiaries, Guangzhou Shengcheng Dunnan Enterprise Management Co., Ltd., and the closure of one of its maternity centers[117] - Additional impairment loss of approximately RMB 6.0 million was recognized this year (2022: RMB 9.2 million), primarily due to increased customer delinquency rates caused by the COVID-19 pandemic[149] Other Financial Information - The company's deferred tax liabilities amounted to RMB 4,041 thousand, indicating future tax obligations[47] - The company's profit before tax for 2023 was RMB 18,001 thousand, with a fair value loss on investment properties of RMB 600 thousand[64] - The company's cash and bank balances were reported at RMB 67 thousand, showing a minimal liquidity position[65] - The company's other income from sources outside its core operations was RMB 25,900 thousand in 2023, down from RMB 37,250 thousand in 2022[70] - The company's deferred tax assets amounted to RMB 9.52 million[126] - The company's other financial assets were valued at RMB 847 thousand[104] - The company's prepayments, deposits, and other receivables amounted to RMB 1.262 million[112] - Capital commitments for subsidiary acquisitions and computer software purchases amounted to RMB 18.8 million as of December 31, 2023 (2022: RMB 13.5 million)[130] - The company completed a share subscription of 30,000,000 shares at HKD 1.47 per share, raising net proceeds of approximately HKD 43.5 million for general working capital and business development[134] - Bank balances and cash stood at approximately RMB 108.3 million as of December 31, 2023 (2022: RMB 13.7 million)[139] - The group's non-current assets include property, plant, and equipment valued at RMB 7,232 million (2022: RMB 9,786 million) and investment properties valued at RMB 24,400 million (2022: RMB 25,000 million)[187] - Investment properties valued at RMB 25,000 thousand[196] - Financing costs amounted to RMB (13,872) thousand[192] Corporate Governance and Meetings - The company will hold its Annual General Meeting on May 31, 2024, with share transfer registration suspended from May 28 to May 31, 2024[197] - The annual results announcement is available on the HKEX website and the company's website, with the annual report to be distributed to shareholders and published online in due course[198] Workforce - The group had 184 employees as of December 31, 2023 (2022: 281 employees), reflecting a reduction in workforce[167]

Financial Performance - For the nine months ended September 30, 2023, the company reported a total revenue of 300 million, representing a 15% increase compared to the prior period[65]. - The net profit for the same period was 45 million, which is a 10% increase year-over-year[65]. - Total revenue for the three months ended September 30, 2023, was RMB 663,000, compared to RMB 743,000 for the same period in 2022, representing a decrease of approximately 10.8%[73]. - Total revenue for the three months ended September 30, 2023, was RMB 56,394, a decrease of 14.1% compared to RMB 65,656 for the same period in 2022[88]. - The Group's total revenue for the nine months ended September 30, 2023, was RMB 226.6 million, compared to RMB 204.5 million for the same period last year, reflecting an increase of approximately 10.8%[95]. - The profit attributable to the owners of the Company for the period was approximately RMB 9.6 million, an increase from RMB 9.0 million in the prior period, primarily due to increased income from trading of medical equipment and consumables[151]. Expenses and Costs - Other operating expenses decreased from approximately RMB 41.9 million in the previous period to about RMB 31.6 million in the current period, primarily due to a reduction in miscellaneous expenses related to the maternal and infant care business from approximately RMB 11.3 million to about RMB 4.2 million[1]. - Short-term lease payments decreased from approximately RMB 4.6 million to about RMB 1.1 million[1]. - Depreciation of property, plant, and equipment decreased from approximately RMB 3.7 million to about RMB 3.1 million, offset by an increase in sales and marketing expenses from RMB 4.4 million to RMB 6.7 million[1]. - Total staff costs recognized in profit or loss for the three months ended September 30, 2023, were RMB 10,974,000, compared to RMB 10,533,000 for the same period in 2022, reflecting an increase of approximately 4.2%[81]. - Cost of inventories sold for the three months ended September 30, 2023, was RMB 37,891,000, a decrease from RMB 60,264,000 in the same period of 2022, indicating a reduction of approximately 37.2%[81]. - Finance costs rose from approximately RMB 9.7 million in the prior period to approximately RMB 10.8 million in the current period, an increase of about 11.3%[173]. Governance and Compliance - The company is committed to maintaining compliance with the GEM Listing Rules, ensuring transparency and accountability in its operations[59]. - The board consists of experienced individuals who regularly meet to discuss operational issues, ensuring effective governance[36]. - The audit committee is composed of independent non-executive directors, ensuring proper oversight of financial reporting[41]. - The company has adopted and complied with the Corporate Governance Code, except for the deviation from code provision C.2.1 regarding the separation of roles of chairman and CEO[166]. - The Board believes that the current structure of having Mr. Zhang Junshen as both chairman and CEO does not impair the balance of power and authority within the company[166]. - The company has confirmed compliance with the Code of Conduct regarding securities transactions by directors for the nine months ended September 30, 2023[196]. Market and Strategic Focus - The company is focused on expanding its market presence and exploring new strategies for growth[38]. - The Group's core business remains optimistic despite economic uncertainties, with a focus on leveraging the current client base for growth[114]. - The Group anticipates that the healthcare industry will become a new economic breakthrough with significant value-added potential post-epidemic[113]. - The Group's strategy includes focusing on the medical equipment industry and expanding its service offerings in the maternal and child postpartum care sector[134]. - The Group aims to continue increasing investment in various businesses to find opportunities amid global economic challenges[141]. Shareholder Information - The company has a total of 300 million shares held by Mr. Zhang Junshen and Mr. Zhang Junwei, indicating significant insider ownership[2]. - As of September 30, 2023, Mr. Zhang Junshen holds 300,000,000 shares, representing 100% ownership in Hero Global[179]. - The Board of Directors does not recommend the payment of an interim dividend for the period, consistent with the prior period where no dividend was paid[151]. Other Financial Metrics - The final dividend declared was HK$10,000,000 (equivalent to RMB 8,977,000) for the nine months ended September 30, 2023, consistent with the previous year[83]. - Basic earnings per share attributable to owners of the Company for the nine months ended September 30, 2023, were calculated based on the total profit for the period, reflecting the company's financial performance[84]. - The Company’s retained profits increased to RMB 81,295 as of September 30, 2023, compared to RMB 71,713 at the beginning of the year[91]. - The Company reported a profit before income tax of RMB 3,209 for the three months ended September 30, 2023, compared to RMB 1,310 for the same period in 2022[88].

Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） 8223 （股份代號： ） 截至二零二三年九月三十日止九個月 第三季度業績公告 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，於 買賣的證券可能會較於聯交所主板買賣的證 GEM 券承受較大的市場波動風險，同時無法保證於 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 GEM GEM 本公告乃遵照聯交所 證券上市規則（「 上市規則」）的規定而提供有關紫元元控股集 團有限公司（「本公司」）的資料，本公司之董事（「董事」）願就本公告共同及個別地承擔全部責 任。董事在作出一切合理查詢後，確認就彼等所知及 ...

[Supplementary Announcement to the Annual Report for the Year Ended December 31, 2022](index=1&type=section&id=Supplementary%20Announcement%20to%20the%20Annual%20Report%20for%20the%20Year%20Ended%20December%2031%2C%202022) [Risk Management Policy](index=1&type=section&id=Risk%20Management%20Policy) The Group implements a comprehensive risk management system, focusing on credit, liquidity, and operational risks through due diligence, multi-level approvals, and continuous monitoring - The Group has established a risk management system targeting credit, liquidity, interest rate, operational, and legal compliance risks, emphasizing comprehensive due diligence, independent data review, and a multi-layer approval process[10](index=10&type=chunk) - The credit risk management process includes several key measures: - **Due Diligence**: The Risk Management Department conducts thorough investigations into client background, financial status, and credit history through on-site visits and online verification[4](index=4&type=chunk) - **Approval Process**: A multi-level review system is in place, where the Risk Management Committee reviews credit assessment reports and grants final approval, with major decisions escalated to the Board of Directors[5](index=5&type=chunk) - **Post-drawdown Management**: This involves routine reviews, daily supervision of repayments, and prompt follow-up on overdue payments to identify potential defaults early[20](index=20&type=chunk) [Leasing Portfolio](index=3&type=section&id=Leasing%20Portfolio) As of December 31, 2022, the Group's net financing lease receivables decreased to RMB 201.2 million, primarily concentrated in medical equipment and largely secured by collateral and guarantees - The Group's total net receivables from financing lease services decreased from **RMB 288.6 million** as of December 31, 2021, to **RMB 201.2 million** as of December 31, 2022[6](index=6&type=chunk)[7](index=7&type=chunk)[14](index=14&type=chunk) Leasing Portfolio by Industry (Net Receivables) | Industry | 2022 (RMB '000) | 2022 (%) | 2021 (RMB '000) | 2021 (%) | | :--- | :--- | :--- | :--- | :--- | | Medical Equipment | 193,397 | 96.2 | 269,553 | 93.4 | | Printing | 4,303 | 2.1 | 15,189 | 5.3 | | Logistics | 3,469 | 1.7 | 3,854 | 1.3 | | **Total** | **201,169** | **100.0** | **288,596** | **100.0** | Leasing Portfolio by Risk Size (Net Receivables) | Risk Size (RMB) | 2022 (RMB '000) | 2022 (%) | 2021 (RMB '000) | 2021 (%) | | :--- | :--- | :--- | :--- | :--- | | Up to 1,000,000 | 173,162 | 86.1 | 260,053 | 90.1 | | 1,000,001 to 3,000,000 | 20,616 | 10.2 | 28,543 | 9.9 | | 3,000,001 to 5,000,000 | 7,391 | 3.7 | - | - | | **Total** | **201,169** | **100.0** | **288,596** | **100.0** | Leasing Portfolio by Guarantee (Net Receivables) | Guarantee Type | 2022 (RMB '000) | 2022 (%) | 2021 (RMB '000) | 2021 (%) | | :--- | :--- | :--- | :--- | :--- | | Collateralized and Guaranteed | 196,411 | 97.7 | 254,832 | 88.3 | | Guaranteed | 3,267 | 1.6 | 33,764 | 11.7 | | Collateralized | 1,491 | 0.7 | - | - | | **Total** | **201,169** | **100.0** | **288,596** | **100.0** |

Revenue and Profitability - The Group recorded a revenue of RMB 15.6 million from maternal and child postpartum care industry services during the Period, reflecting a decline due to epidemic control measures[4]. - Revenue from the medical equipment and consumables trading business reached RMB 147.2 million, marking a significant growth in the Group's revenue structure[5]. - Total revenue for the six months ended June 30, 2023, was RMB 175,623,000, an increase from RMB 142,466,000 in the same period of 2022, representing a growth of approximately 23.2%[103]. - Income from postpartum care services was RMB 15,571,000 for the six months ended June 30, 2023, compared to RMB 24,712,000 in the same period of 2022, indicating a decline of about 37.1%[103]. - Profit attributable to owners of the Company decreased to approximately RMB 6.1 million for the six months ended June 30, 2023, down from RMB 8.1 million in the prior period[13]. - Profit before income tax for the six months ended June 30, 2023, was RMB 7,336,000, down from RMB 9,698,000 in the same period of 2022, reflecting a decrease of approximately 24.4%[103]. - Total comprehensive income for the period attributable to owners of the Company was RMB 6,115,000, compared to RMB 8,103,000 in the same period of 2022, indicating a decline of about 24.5%[103]. Expenses and Costs - Other operating expenses decreased from approximately RMB 24.4 million in the prior period to about RMB 21.0 million in the current period, primarily due to reduced miscellaneous expenses in the maternal and child postpartum care business[11]. - The Group's total employee costs for the period were approximately RMB 20.7 million, slightly up from RMB 20.6 million in the prior period[19]. - Staff costs for the six months ended June 30, 2023, were RMB 20,712,000, slightly increasing from RMB 20,639,000 in the same period of 2022, showing a marginal increase of about 0.4%[103]. Dividends and Shareholder Information - The Group does not recommend the payment of an interim dividend for the Period, consistent with the prior period[12]. - The final dividend declared for the period is HKD 0.025 per share, totaling HKD 10,000,000 (approximately RMB 9,140,000)[58]. - The ultimate controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, are deemed to be interested in 75.0% of the issued share capital of the Company[1]. - Mr. Zhang Junshen holds 300,000,000 Shares, which includes 219,801,980 Shares held by Hero Global and 80,198,020 Shares as a party acting-in-concert with Mr. Zhang Junwei[2]. - Mr. Zhang Junwei also holds 300,000,000 Shares, consisting of 80,198,020 Shares held by Icon Global and 219,801,980 Shares as a party acting-in-concert with Mr. Zhang Junshen[3]. Financial Position and Assets - As of June 30, 2023, trade receivables amounted to RMB 100,091,000, down from RMB 132,435,000 as of December 31, 2022, indicating a reduction of approximately 24.3%[83]. - The company maintained a strong cash position with bank balances and cash totaling RMB 18,533,000 as of June 30, 2023, compared to RMB 13,707,000 at the end of 2022[128]. - The company’s total liabilities decreased from RMB 33,348,000 to RMB 28,500,000, a decline of approximately 14.5%[65]. - The net current assets as of June 30, 2023, were RMB 209,775,000, down from RMB 233,689,000 at the end of 2022[128]. - The total reportable segment assets as of June 30, 2023, amounted to RMB 532,483,000, with finance leasing assets at RMB 241,750,000, trading business assets at RMB 205,670,000, and postpartum care service assets at RMB 85,063,000[160]. Compliance and Governance - The Company has confirmed compliance with the Code of Conduct regarding securities transactions by the Directors for the reporting period[33]. - The Audit Committee has reviewed the unaudited condensed consolidated financial statements for the six months ended 30 June 2023, ensuring compliance with applicable accounting standards and GEM Listing Rules[54]. - The Company has adopted the corporate governance practices as per the GEM Listing Rules, ensuring proper regulation of business activities and decision-making processes[31]. - The independent non-executive Directors confirmed compliance with the Deed of Non-competition by all controlling shareholders during the period[44]. Market Outlook and Strategy - The Group anticipates that the health industry will become a new economic breakthrough point with significant value-added potential post-epidemic[5]. - The Group plans to continue increasing investment in various businesses despite the grim global economic situation[6]. - The management discussed strategies for market expansion and new product development, although specific figures were not disclosed in the provided content[89]. Cash Flow and Investments - Net cash generated from operating activities for the six months ended June 30, 2023, was RMB 21,481,000, compared to a net cash used of RMB 32,253,000 in the same period of 2022[136]. - Net cash used in investing activities was RMB 6,214,000 for the six months ended June 30, 2023, compared to a net cash generated of RMB 3,810,000 in the same period of 2022[136]. - The net decrease in cash and cash equivalents for the six months ended June 30, 2023, was RMB 41,810,000, an improvement from a decrease of RMB 68,487,000 in the same period of 2022[136]. Segment Performance - Reportable segment revenue for finance leasing service was RMB 4,975,000, while postpartum care service generated RMB 11,165,000, and trading of medical equipment and consumables reported a loss of RMB 832,000[143]. - Reportable segment profit before income tax for the same period was RMB 7,336,000, with a profit of RMB 2,749,000 from finance leasing, RMB 16,999,000 from trading, and a loss of RMB 2,208,000 from postpartum care services[160].

Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） 8223 （股份代號： ） 截至二零二三年六月三十日止六個月 中期業績公告 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，於 買賣的證券可能會較於聯交所主板買賣的證 GEM 券承受較大的市場波動風險，同時無法保證於 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本報告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 GEM GEM 本公告乃遵照聯交所 證券上市規則（「 上市規則」）的規定而提供有關紫元元控股集 團有限公司（「本公司」）的資料，本公司之董事（「董事」）願就本報告共同及個別地承擔全部責 任。董事在作出一切合理查詢後，確認就彼等所知及所信 ...

Revenue and Profit Performance - Total revenue for Q1 2023 was RMB 61.61 million, a significant increase from RMB 31.75 million in Q1 2022[11] - Revenue from medical equipment and consumables trading surged to RMB 45.01 million in Q1 2023, up from RMB 8.11 million in Q1 2022[11] - Postpartum care services revenue decreased to RMB 7.67 million in Q1 2023 from RMB 11.87 million in Q1 2022[11] - Finance leasing income dropped to RMB 8.67 million in Q1 2023 compared to RMB 11.27 million in Q1 2022[11] - Profit before income tax increased to RMB 2.44 million in Q1 2023 from RMB 2.13 million in Q1 2022[11] - Net profit attributable to owners of the company was RMB 2.08 million in Q1 2023, slightly down from RMB 2.16 million in Q1 2022[11] - Earnings per share (basic and diluted) were RMB 0.52 cents in Q1 2023, compared to RMB 0.54 cents in Q1 2022[11] - Revenue for the period includes finance leasing income, interest income on loan receivables, income from postpartum care services, and income from trading of medical equipment and consumables in the PRC[35] - Revenue from finance leasing services decreased to RMB8.67 million in Q1 2023 from RMB11.27 million in Q1 2022[50] - Revenue from maternal and child postpartum care services decreased to RMB7.67 million in Q1 2023 from RMB11.87 million in Q1 2022[50] - Revenue from trading of medical equipment and consumables increased significantly to RMB45.01 million in Q1 2023 from RMB8.11 million in Q1 2022[50] - The Group's medical equipment and consumables trading business achieved revenue of RMB45.0 million in Q1 2023[67] - Profit attributable to owners of the Company was approximately RMB2.08 million in Q1 2023, compared to RMB2.16 million in Q1 2022[69] - Revenue increased by approximately RMB 29.9 million or 94.0%, from RMB 31.8 million in the prior period to RMB 61.6 million in the current period, primarily driven by a significant increase in medical equipment and consumables trade revenue from RMB 8.1 million to RMB 45.0 million[83] - Revenue increased by approximately RMB29.9 million (94.0%) from RMB31.8 million to RMB61.6 million, driven by a significant rise in income from trading medical equipment and consumables from RMB8.1 million to RMB45.0 million[103] - Medical equipment and consumables trading business achieved revenue of RMB45.0 million, marking a breakthrough growth in the company's revenue structure[100] - Finance leasing income decreased from RMB11.8 million to RMB8.9 million, while postpartum care services income decreased from RMB11.9 million to RMB7.7 million[103] - Profit and total comprehensive income attributable to owners of the company decreased from RMB 2.2 million to RMB 2.1 million, primarily due to a decrease in revenue from finance leasing services and maternal and child postpartum care industry services, as well as an increase in finance costs[114] Costs and Expenses - Total interest expense on financial liabilities not measured at fair value through profit or loss was RMB 3,990 thousand in 2023, compared to RMB 3,186 thousand in 2022[37] - Current tax for PRC Enterprise Income Tax was RMB 234 thousand in 2023, up from RMB 213 thousand in 2022[39] - Deferred tax increased significantly to RMB 413 thousand in 2023 from RMB 24 thousand in 2022[39] - Total staff costs decreased to RMB 10,196 thousand in 2023 from RMB 11,259 thousand in 2022[44] - Cost of inventories sold surged to RMB 36,532 thousand in 2023 from RMB 6,611 thousand in 2022[44] - Research and development costs recognized as an expense increased to RMB 848 thousand in 2023 from RMB 123 thousand in 2022[44] - Short-term lease payments decreased to RMB 356 thousand in 2023 from RMB 1,411 thousand in 2022[44] - Medical equipment and consumables sold cost increased to approximately RMB 36.5 million from RMB 6.6 million in the prior period[84] - Finance costs increased from approximately RMB 3.2 million to RMB 4.0 million, primarily due to an increase in interest on bank and other borrowings from RMB 3.0 million to RMB 3.7 million[90] - Cost of sales for medical equipment and consumables business increased to approximately RMB36.5 million from RMB6.6 million in the prior period[107] - Staff costs decreased from RMB10.1 million to approximately RMB9.5 million, primarily due to a reduction in headcount[108] - Other operating expenses decreased from approximately RMB12.0 million to RMB10.4 million, mainly due to reductions in postpartum care business expenses, short-term lease payments, and depreciation of property, plant, and equipment[111] - Other operating expenses decreased from approximately RMB 12.0 million to RMB 10.4 million, mainly due to reductions in miscellaneous expenses for maternal and child postpartum care business (from RMB 3.2 million to RMB 2.1 million), short-term lease payments (from RMB 1.4 million to RMB 0.4 million), and depreciation of property, plant, and equipment (from RMB 1.9 million to RMB 1.1 million)[112] Taxation - The tax rate for most PRC subsidiaries is 25%, except for one subsidiary recognized as a high technology enterprise, which enjoys a preferential tax rate of 15%[39] - Certain PRC subsidiaries qualified as small low-profit enterprises, with taxable income not exceeding RMB 1.0 million taxed at 12.5%, and income exceeding RMB 1.0 million but not exceeding RMB 3.0 million taxed at 50% of the taxable income[90] - The Group's subsidiaries in China are subject to an enterprise income tax rate of 25%, except for one subsidiary which qualifies for a preferential rate of 15%[59] Corporate Governance and Shareholding - The company's controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, are deemed to be interested in 75.0% of the issued share capital of the company[1] - The company's issued share capital as of 31 March 2023 was HK$40,000,000, with 400,000,000 ordinary shares issued at HK$0.1 per share[114] - Mr. Zhang Junshen and Mr. Zhang Junwei each hold 300,000,000 shares, representing a 75% stake in the company[116] - The company did not recommend the payment of an interim dividend for the period[114] - The company's capital structure has remained unchanged since its listing on the GEM of the Stock Exchange on 9 July 2018[114] - The company confirmed that all directors complied with the Code of Conduct regarding securities transactions for the three months ended 31 March 2023[135] - The Audit Committee reviewed the unaudited condensed consolidated financial statements and confirmed compliance with applicable accounting standards and GEM Listing Rules[139] - The company has not purchased, sold, or redeemed any of its listed securities during the period[131] - The company maintains high corporate governance standards, with compliance to the CG Code except for a deviation from code provision C.2.1[129] - The controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, are deemed to be interested in 75.0% of the issued share capital of the company through Hero Global and Icon Global respectively[150] - Ms. Tang Yiping, the spouse of Mr. Zhang Junshen, is deemed to be interested in all shares in which Mr. Zhang Junshen is interested[150] - As of 31 March 2023, the directors were not aware of any other person (other than the disclosed directors or chief executive) who had or was deemed to have interests or short positions in the company's shares, underlying shares, or debentures[150] - The company and its subsidiaries did not purchase, sell, or redeem any of the company's listed securities during the period and up to the date of the report[152] - The company has adopted and complied with the Corporate Governance Code (CG Code) except for a deviation from code provision C.2.1[153] - The Audit Committee consists of non-executive director Mr. Lyu Di and independent non-executive directors Mr. Chan Chi Fung Leo and Dr. Deng Bin, with Mr. Chan Chi Fung Leo serving as the chairman[162] - The Audit Committee has reviewed the unaudited condensed consolidated financial statements for the three months ended 31 March 2023 and considers them to be in compliance with applicable accounting standards, GEM Listing Rules, and other legal requirements[168] - The roles of chairman and chief executive officer are both held by Mr. Zhang Junshen, which the Board believes ensures strong and consistent leadership without impairing the balance of power and authority[171] - The Group has established an Audit Committee in compliance with the GEM Listing Rules and the CG Code, with written terms of reference[172] - The Board comprises experienced and high-caliber individuals who meet regularly to discuss operational issues[171] - The Board has full confidence in Mr. Zhang Junshen's dual role, believing it benefits the Company's business prospects[171] - The Audit Committee was established pursuant to a resolution passed by the Directors on 12 June 2018[172] Business Strategy and Outlook - The Group recorded a segmental loss in maternal and child postpartum care services due to pandemic-related restrictions[75] - The company remains optimistic about sustaining its core business despite economic uncertainties caused by Covid-19, focusing on leveraging its existing client base and exploring opportunities in the healthcare industry[102] - The healthcare industry is expected to be a new economic breakthrough with significant value-added potential post-pandemic, prompting the company to focus on medical equipment finance leasing and trading[102] - The company has strategically entered the medical equipment and consumables trading business, targeting sectors such as medical aesthetics, dental, maternal and child care, and large hospital equipment[100] Financial Position and Equity - Total equity attributable to owners of the company increased to RMB 308.94 million as of March 31, 2023, from RMB 306.86 million at the start of the year[13] - Reversal of impairment loss of approximately RMB 0.9 million was recognized, mainly due to a decrease in total trade receivables[87]

Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） 8223 （股份代號： ） 截至二零二三年三月三十一日止三個月 第一季度業績公告 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，於 買賣的證券可能會較於聯交所主板買賣的證 GEM 券承受較大的市場波動風險，同時無法保證於 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 GEM 本公告乃遵照 證券上市規則的規定而提供有關紫元元控股集團有限公司（「本公司」）的資 料，本公司之董事（「董事」）願就本公告共同及個別地承擔全部責任。董事在作出一切合理查 詢後，確認就彼等所知及所信，本公告所載資料在各重要方 ...